{
    "clinical_study": {
        "@rank": "107655", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "5 placebo pills per day, 24 weeks"
            }, 
            {
                "arm_group_label": "Vitamin D", 
                "arm_group_type": "Experimental", 
                "description": "5 vitamin D3 pills per day, 24 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "1. To investigate the effects of vitamin D3 supplement on metabolic phenotypes including\n           BMI, blood pressure, vitamin D metabolites, liver function, renal function and\n           circulating mineral biomarkers;\n\n        2. To determine the effects of genetic variants on bioavailability of vitamin D3\n           supplements and its associations with metabolic phenotypes."
        }, 
        "brief_title": "Vitamin D Intervention Trial in Healthy Chinese,Phase II", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Vitamin D Deficiency", 
        "condition_browse": {
            "mesh_term": "Vitamin D Deficiency"
        }, 
        "detailed_description": {
            "textblock": "The intervention study will mainly investigate bioavailability and effects of vitamin D3\n      supplements on metabolic traits, and also to what extent that genetic variants will modify\n      effect of vitamin D3 supplements on 25(OH)D among the individuals with vitamin D deficiency.\n      A total of 400 eligible subjects (200 in each group) will receive either vitamin D3\n      supplements or placebo for 24 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age: 20-45 years. with vitamin D deficiency or insufficiency (25(OH)D < 75 nmol/l)\n\n        Exclusion Criteria:\n\n          -  BMI < 18.5 kg/m2, or BMI \u2265 25 kg/m2\n\n          -  Total intake of calcium from diet or supplements >1200mg/d, or fasting serum calcium\n             level \u22652.75 mmol/l\n\n          -  Participating in other clinical studies within previous 3 months\n\n          -  Taking vitamin D supplements within previous 3 months\n\n          -  Using medications that may affect vitamin D metabolism in previous 3 months;\n\n          -  Concomitant with clinical conditions, like liver dysfunction (serum alanine\n             transaminase (ALT) \u226540 U/L; and/or aspartate transaminase (AST) \u226540 U/L; Glutamyl\n             transpeptidase \uff08GGT\uff09\u226550 U/L; serum creatinine < 50 or > 120 \u00b5mol/L; urea nitrogen\n             (UN) < 7 or > 18 mg/dl, and/or urine acid <90 or >420 \u00b5mol/L; which may affect\n             vitamin D metabolism;\n\n          -  History of drug or alcohol abuse (>40 g/d)\n\n          -  Women during pregnancy or lactation\n\n          -  Individuals with mental disorders or current use of antidepressants, the conditions\n             which may affect him or her understanding and unwillingness to the intervention;\n\n          -  Having clinically diagnosed AIDS, hepatitis A, hepatitis B, tuberculosis and other\n             infectious diseases."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01998763", 
            "org_study_id": "KSCX2-EW-R-10-VDII", 
            "secondary_id": "KSCX2-EW-R-10"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "placebo capsules have similar appearance and smell as 400IU vitamin D3 capsules,", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Vitamin D", 
                "description": "Vitamin D2000 IU per day", 
                "intervention_name": "Vitamin D", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "vitamin D", 
            "metabolite", 
            "genotype"
        ], 
        "lastchanged_date": "November 25, 2013", 
        "location": {
            "contact": {
                "email": "yaopang@sibs.ac.cn", 
                "last_name": "Pang Yao", 
                "phone": "+86-21-54920972"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China"
                }, 
                "name": "Institute for Nutritional Sciecnes, Chinese Acadamy of Sciences"
            }, 
            "investigator": {
                "last_name": "Xu Lin, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Knowledge Innovation Project of CAS - Genetic and Nutritional Association Studies on Metabolism-related Diseases in Chinese Population -- Vitamin D Intervention Study", 
        "overall_contact": {
            "email": "yaopang@sibs.ac.cn", 
            "last_name": "Pang Yao", 
            "phone": "+86-21-54920972"
        }, 
        "overall_official": {
            "affiliation": "Institute for Nutritional Sciecnes, Chinese Acadamy of Sciences", 
            "last_name": "Xu Lin, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Serum 25(OH)D concentration will be assayed by utilizing a liquid chromatography-mass spectrometry (LC-MS) method", 
            "measure": "25-hydroxyvitamin D", 
            "safety_issue": "Yes", 
            "time_frame": "0\uff0c12\uff0c24 week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01998763"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chinese Academy of Sciences", 
            "investigator_full_name": "Xu Lin", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Serum 1,25(OH)2D concentration will be assayed by utilizing a liquid chromatography-mass spectrometry (LC-MS) method", 
                "measure": "1,25-dihydroxycholecalciferol", 
                "safety_issue": "No", 
                "time_frame": "0,12,24 week"
            }, 
            {
                "description": "Serum 24,25(OH)2D concentration will be assayed by utilizing a liquid chromatography-mass spectrometry (LC-MS) method", 
                "measure": "24,25-Dihydroxycholecalciferol", 
                "safety_issue": "No", 
                "time_frame": "0,12,24 week"
            }, 
            {
                "description": "Serum 1,24,25(OH)3D concentration will be assayed by utilizing a liquid chromatography-mass spectrometry (LC-MS) method", 
                "measure": "1,24,25(OH)3D", 
                "safety_issue": "No", 
                "time_frame": "0,12,24 week"
            }, 
            {
                "description": "ELISA", 
                "measure": "parathyroid hormone", 
                "safety_issue": "No", 
                "time_frame": "0,12,24 week"
            }, 
            {
                "description": "ELISA", 
                "measure": "Vitamin D binding protein", 
                "safety_issue": "No", 
                "time_frame": "0,12,24 week"
            }
        ], 
        "source": "Chinese Academy of Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chinese Academy of Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}